| 主权项 |
1. A pharmaceutical composition for treating hepatitis B virus infection, comprising the crystal entecavir as the active ingredient and one or more pharmaceutically acceptable excipients, wherein:
the crystal entecavir has the x-ray diffraction pattern of FIG. 1 and is present at an amount of from 0.001 mg to 25 mg; and the one or more pharmaceutically acceptable excipients comprise one or more of diluents, adhesives, glidants and disintegrants, wherein the diluents comprise one or more compounds selected from lactose, starch, sucrose, glucose, mannitol, xylitol, maltitol, dextrin, calcium sulfate and calcium phosphate, wherein the diluent is present at an amount of from 50% to 90% by weight of the total composition; the adhesives comprise one or more compounds selected from hydroxypropylmethylcellulose, alginic acid, sodium alginate, carbomer, poloxamer, and gelatin, wherein the adhesive is present in an amount of from 2% to 18% by weight of the total composition; the glidants comprise one or more compounds selected from silica, stearic acid, sodium stearate, calcium stearate, sodium lauryl sulfate, sucrose fatty acid ester, and talcum powder, wherein the glidant is present in an amount of from 0.1% to 5% by weight of the total composition; and the disintegrants comprising one or more compounds selected from hydroxypropyl cellulose, croscarmellose sodium, and crospovidone, the disintegrant is present in an amount of from 1% to 5% by weight of the total composition. |
